Budaxiu Potassium Chloride Sustained Release Tablets

Potassium is the main cation in cells, with a concentration of 150-160 mmol/L; while the main cation outside cells is sodium ion, with a potassium concentration of only 3.5-5 mmol/L. The body mainly relies on Na-K-ATPase on the cell membrane to maintain the concentration difference between K and Na in cells. The acid-base balance in the body has an impact on potassium metabolism. For example, when acidosis occurs, H enters the cell. In order to maintain the potential difference of the cell, K is released outside the cell, causing or aggravating hyperkalemia. Metabolic disorders can also affect acid-base balance. The normal intracellular and extracellular potassium ion concentration and concentration difference are closely related to some important functions of cells, including maintaining carbohydrate metabolism, glycogen storage, protein metabolism, intracellular osmotic pressure and acid-base balance, myocardial excitability and conductivity; maintaining normal skeletal muscle tension and nerve impulse conduction, and increasing the tension of intestinal, uterine and bronchial smooth muscles.

Ingredients: Potassium chloride. Molecular formula: KCl, molecular weight: 74.55.

This product is a sugar-coated tablet, which appears white after removing the sugar coating and contains an appropriate amount of excipients.

1. Treatment of hypokalemia caused by various reasons, such as insufficient food intake, vomiting, severe diarrhea, use of potassium-excreting diuretics, hypokalemic familial periodic paralysis, long-term use of glucocorticoids and supplementation of hypertonic glucose, etc. 2. Prevention of hypokalemia When patients have potassium loss, especially if hypokalemia is harmful to patients (such as patients with digitalis), preventive potassium salt supplementation is required, such as eating very little, severe or chronic diarrhea, long-term use of adrenocortical hormones, potassium-losing nephropathy, and Bartter's syndrome, etc. 3. Digitalis poisoning causes frequent, multifocal premature beats or rapid arrhythmias.

Adults: 1g each time, twice a day, morning and evening, or as directed by a doctor.

1. Oral administration may occasionally cause gastrointestinal irritation symptoms, such as nausea, vomiting, throat discomfort, chest pain (esophageal irritation), abdominal pain, diarrhea, and even peptic ulcer and bleeding. It is more likely to occur when the patient is on an empty stomach, takes a large dose, or has existing gastrointestinal diseases. 2. Hyperkalemia. It is prone to occur when the patient is overdosed or has existing renal damage. It manifests as weakness, fatigue, numbness of the hands, feet, lips, and mouth, unexplained anxiety, confusion, difficulty breathing, slow heart rate, arrhythmia, conduction block, and even cardiac arrest. The electrocardiogram shows high and sharp T waves, and gradually prolongs the P-R interval. The P wave disappears, the QRS wave widens, and a sine wave appears. Once hyperkalemia occurs, it should be treated immediately: (1) Immediately stop potassium supplementation, avoid potassium-containing diets, drugs, and potassium-sparing diuretics. (2) Intravenous infusion of high concentrations of potassium

Hyperkalemia; patients with scanty urine output and urinary retention.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: The kidneys of the elderly have a reduced ability to clear potassium, and are more likely to develop hyperkalemia when using potassium salts. Follow-up checks of blood potassium should be performed during medication.

1. Adrenal glucocorticoids, especially those with more obvious mineralocorticoid effects, adrenal mineralocorticoids and adrenocorticotropic hormone (ACTH), can promote urinary potassium excretion, and when used together, the efficacy of potassium salts is reduced. 2. Anticholinergic drugs can aggravate the gastrointestinal irritation of oral potassium salts, especially potassium chloride. 3. Non-steroidal anti-inflammatory analgesics aggravate the gastrointestinal reactions of oral potassium salts. 4. When using stored blood (30mmol/L of potassium for less than 10 days of storage, 65mmol/L of potassium for more than 10 days of storage), taking potassium-containing drugs and potassium-sparing diuretics, the chance of hyperkalemia increases, especially in patients with renal impairment. 5. Angiotensin-converting enzyme inhibitors and cyclosporine can inhibit aldosterone secretion and reduce urinary potassium excretion. Hyperkalemia is prone to occur when used together. 6. Heparin can inhibit the synthesis of aldosterone and reduce urinary potassium excretion. Hyperkalemia is prone to occur when used together; in addition, heparin can increase the chance of gastrointestinal bleeding. 7. Sustained-release potassium salts can inhibit the intestinal absorption of vitamin B12.

Seal and store in a dry place.

0.5 g

24 months.